Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...
Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...
Naples Daily News on MSN8d
Red Dye No. 3 versus Red 40: What is the difference, why is only one being banned?The U.S. Food and Drug Administration banned Red No. 3 last dye, leading those to think Red Dye No. 40 could be next. How are ...
HealthDay on MSN3d
Adderall shortage sparks scramble for ADHD medication alternativesAdderall shortages have prompted doctors to switch kids with attention-deficit/hyperactivity disorder to other forms of ...
Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know ...
The Food and Drug Administration announced last week that it will revoke authorization for FD&C Red No. 3 in food and ...
The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...
A national shortage in a common treatment for attention-deficit hyperactivity disorder was associated with changes in stimulant prescriptions filled for children over recent years, a new study ...
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback